| P476 | EWS-FLI1 expression level modulates T-cell mediated tumor apoptosis in Ewing sarcoma. | Claire M. Julian; Ariel N. Klinghoffer; Hether M. Bernard, MD; Linda M. McAllister-Lucas; Kelly M. Bailey, MD, PhD | Solid tumors; T cell; Tumor microenvironment |
| P477 | HMBD-002-V4: A novel anti-VISTA antibody that uniquely binds murine and human VISTA and potently inhibits tumor growth by remodeling the immunosuppressive tumor microenvironment | Jerome D. Boyd-Kirkup, PhD; Dipti Thakkar, PhD; Vicente Sancenon, PhD; Siyu Guan, PhD; Konrad Paszkiewicz, PhD; Piers Ingram, PhD | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; Myeloid cells; MDSC; Systems biology; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P478 | Platelets as immune suppressors in anti-cancer immune responses | Ana Micaela M. Carnaz Simões; Morten O. Holström, PhD; Mads H. Andersen, PhD; Per Thor Straten, PhD; | Immune suppression; Immune tolerance; T cell; Tumor evasion |
| P479 | NG-641: an oncolytic T-SIGn virus targeting cancer-associated fibroblasts in the stromal microenvironment of human carcinomas | Matthieu Besneux; Brian R. Champion, PhD; Nalini Marino; Marilena Patsalidou; Gianfranco di Genova; Sam Illingworth; Stefania Fedele; Lorna Slater; Darren Plumb; Katy West; Joshua Freedman, BS; Len Seymour; Kerry S. Fisher, MD PhD; Alice C. Brown, PhD | Chemokine; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P480 | Transcriptomic characterization of tumor vs. peripheral blood NK cells in head and neck cancer patients | Fernando Concha-Benavente, MD, PhD; Robert Ferris | Immune suppression; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P481 | The epigenetic underpinnings of regulatory T cell fragility in the tumor microenvironment | Becky Dadey, BS; Abigail E. Overacre-Delgoffe, PhD; Ting Wang; Zhe Sun; Rong Zhang, MS; Wei Chen; Natalie Rittenhouse; Amanda Poholek; Tracy Tabib; Robert Lafyatis; Creg Workman, PhD; Dario A. Vignali, PhD; | Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P482 | Humanization and characterization of novel, best in class isoform-specific anti-TGFβ monoclonal antibodies | Matteo Brioschi; Pamela Cheou; Jacques Van Snick, PhD; Catherine Uyttenhove, PhD; George Coukos, MD, PhD; Gerd Ritter; Steven M. Dunn, PhD | Antibody; Cytokine; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P483 | Iron and HLA-G: Neglected immunosuppressive molecules in the human microenvironment | Xian P. Jiang; Robert Elliott; | NK/NK T cell; Tumor microenvironment |
| P484 | Pharmacokinetics, pharmacodynamics, and safety of FLX475, an orally-available, potent, and selective small-molecule antagonist of CCR4, in healthy volunteers | Primary Author - Sjoerd van Marle, M.D.; Ewoud-Jan van Hoogdalem, Ph.D., R.Ph.; Daniel Johnson; Abood Okal, PhD; Paul D. Kassner, PhD; David J. Wustrow, PhD; William Y. Ho, MD, PhD; Steven A. Smith; | Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor microenvironment |
| P485 | Testing of two bispecific SNIPER™ antibodies targeting mouse tumor-infiltrating Tregs | Anna Hoefges, MS; Bonnie Hammer; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Jacquelyn A. Hank, PhD; Bryan Glaser, Ph.D.; Lucas Bailey, PhD; Roland Green, PhD; Paul M. Sondel, MD, PhD | Antibody; Immune adjuvant; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P486 | Antisense oligonucleotides targeting CD39 and PD-L1 modulate the immunosuppressive tumor microenvironment and have potent anti-tumor activity | Frank Jaschinski, PhD; Tamara Thelemann; Frank Jaschinski, PhD; Richard Klar, PhD; Monika Schell; Lisa Hinterwimmer; Sven Michel; Melanie Buchi; Abhishek S. Kashyap; Alfred Zippelius, MD | Immune suppression; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P487 | The role of MultiOmyx in illustrating the pancreatic tumor microenvironment | Juncker-Jensen Juncker-Jensen, PhD; Juncker-Jensen Juncker-Jensen, PhD; Juncker-Jensen Juncker-Jensen, PhD; Jun Fang; Judy Kuo; Mate Nagy; Qingyan Au; Eric Leones; Flora Sahafi; RaghavKrishna Padmanabhan; Nicholas Hoe; Josette William, PhD, MD; | Antibody; Biomarkers; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment; Tumor stroma |
| P488 | Targeting hIDO1 with 3rd generation antisense oligonucleotides for modulation of the tumor microenvironment | Richard Klar, PhD; Sandra Kallert, PhD; Tamara Thelemann; Sven Michel; Monika Schell; Lisa Hinterwimmer; Alfred Zippelius, MD; Frank Jaschinski, PhD | Immune suppression; Myeloid cells; MDSC; Metabolism; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P489 | Prognostic significance of tumor-associated macrophage content in head and neck squamous cell carcinoma: A meta-analysis | Ayan T. Kumar, BS; Alexander Knops, BA; Brian P. Swendseid, MD; Ubaldo Martinez-Outschoom, MD; Larry Harshyne, PhD; Nancy Philp, PhD; Ulrich Rodeck, MD PhD; Christopher M. Snyder; Adam Luginbuhl, MD; David Cognetti, MD; Jennifer Johnson, MD; Joseph Curry, MD; Joseph Curry, MD; | Autoimmunity; Immune adjuvant; Immune monitoring; Immune suppression; Monocyte/Macrophage; Myeloid cells; Targeted therapy; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P490 | Characterization of the tumor immune microenvironment in treatment-naïve EGFR-mutant NSCLC uncovers a suppressed immune phenotype | Xiuning Le; Alexandre Reuben; Marcelo V. Negrao, MD; Won-Chul Lee, PhD; Edwin Parra; Carmen Behrens, MD; Humam Kadara, PhD; Ignacio Wistuba, MD; Jianjun Zhang, MD, PhD; John V. Heymach; | Immune suppression; Tumor microenvironment |
| P491 | The DNA methyltransferase inhibitor, guadecitabine, has beneficial immunomodulatory effects on myeloid derived suppressor cells, and augments adoptive immunotherapy for solid tumors | Andrea Luker, Ph.D. candidate; Harry D. Bear, M.D., Ph.D.; Andrea Luker, Ph.D. candidate; Daniel H. Conrad, Ph.D.; Laura Graham; | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Immune suppression; Myeloid cells; MDSC; Solid tumors; Tumor microenvironment |
| P492 | Myeloid-derived suppressor cells (MDSC) assessment using a fully automated sequential chromogenic multiplex assay | Anna Martirosyan, Dr; Assil Benchaaben; Aurélie Collignon, MS; Emilie Bonzom, Trainee; Matthieu Duval, Apprentice; Emmanuel Prestat, PhD; Christophe Haond; Jacques Fieschi, PhD | Biomarkers; Immune contexture; Immune monitoring; Immune suppression; Myeloid cells; MDSC; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P493 | B cells in glioblastoma are associated with diminished survival | Ileana S. Mauldin, PhD; Jasmin Jo, MD; Nolan A. Wages, PhD; Samuel J. Young, BS; Loren D. Erickson, PhD; Maria-Beatriz S. Lopes, MD, PhD; Craig L. Slingluff, Jr., MD; Camilo E. Fadul, MD, FAAN | B cell; Biomarkers; Immune suppression; Tumor infiltrating lymphocytes (TILs) |
| P494 | Targeting the CCR2/MCP-1 chemokine axis for cancer therapy | Payal Mittal; Tatiana Akimova; Craig Leach; Jose Clemente; Matthew Sender; Liqing Wang; Joseph Marino; Yao Chen; Peiling Chen; Brandon Turunen; Wayne W. Hancock, MD, PhD; | Immune monitoring; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P495 | Pegfilgrastim, but not Plinabulin, generates a blood myeloid cell (BMC) repertoire with a predominant immunosuppressive phenotype | Douglas W. Blayney, MD; Stephan Ogenstad; Yuankai Shi; Lihua Du; Lan Huang; Ramon Mohanlal, MD, PhD, MBA; | Clinical study; Clinical trial; Granulocyte; Immune contexture; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; T cell; Tumor microenvironment |
| P496 | Innate and adaptive immune responses to metastatic colorectal cancer differ by sex and correlate with survival | Anita L. Ray, PhD; Robert A. Nofchissey, BS; Sarah F. Adams, MD; William T. Berry; Katherine T. Morris, MD, FACS; | Cytokine; Immune contexture; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P497 | Study of anti-HER2 CAR T cells in the immunosuppressive ependymoma tumor microenvironment | Anandani Nellan, MD; Marissa Kane; Andrea Griesinger; Andrew Donson; Vladimir Amani; Nicholas Foreman; Davis Witt; Jean Mulcahy Levy | CAR T cells; Pediatric tumors; Solid tumors; Tumor microenvironment |
| P498 | Characterization of the tumor microenvironment in a spontaneous mouse model of cholangiocarinoma: a robust model for evaluating therapeutic interventions for treating the disease | Luis I. Ruffolo, MD; Katherine M. Jackson, MD; Joseph D. Murphy, M.Sc; Nathania Figueroa, MD; Brian A. Belt, JD; David C. Linehan, MD; Peter A. Prieto, MD, MPH; | Checkpoint blockade; Granulocyte; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor stroma |
| P499 | Correlation of immune escape mediated defects in the HLA class I antigen-presenting machinery with the immune cell infiltration and prognosis in oral squamous cell carcinoma | Barbara Seliger, MD, PhD; Claudia Wickenhauser, MD, PhD | Antigen presenting cells; Tumor evasion; Tumor microenvironment |
| P500 | Novel bispecific antibody preferentially and efficiently depletes tumor-associated immunosuppressive myeloid cells and enhances therapeutic responses to PD-L1 blockade in immune-excluded tumor model | Seng-Lai Tan, PhD; Sangeetha Palakurthi, PhD; Jacqueline Lee | Antibody; Chemokine; Cytokine; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P501 | Multiplex immunofluorescence evaluation of immune cell relationships within PDAC resection tissues using tailored analysis of multi-spectral image component data | Alison Bigley, CSci, FIBMS; Lorcan Sherry, PhD; Mark Anderson, BSc; Mariana Beltran; Dawn B. Lyster, MSc; Mike Millar; | Biomarkers; Immune contexture; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P502 | Novel approach of modulating immune cell metabolism in the tumor microenvironment to enhance efficacy of immunotherapy | Frank Boriello, MD/PhD; HongBum Lee; Vincent O'Neil; Ted Kim, PhD; James Lederer, PhD; Sanghee Yoo, PhD; | Immune suppression; MDSC; Metabolism; Regulatory T cell (Treg cell); Tumor microenvironment |
| P503 | Characterization of the immune desert in metastatic non-small cell lung cancer (NSCLC) and the use of cell proliferation to predict clinical response to immune checkpoint inhibitors (ICIs) | Jason Zhu, MD; Matthew K. Labriola, MD; Daniele Marin, MD; Shannon J. McCall, MD; Edwin Yau, MD, PhD; Grace K. Dy; Sarabjot Pabla, MSc, PhD, BS; Sean T. Glenn, PhD; Carl D. Morrison, MD, DVM; Daniel J. George, MD; Tian Zhang, MD; Jeffrey M. Clarke, MD | Biomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment |
| O35 | Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity | Esra Akbay, PhD; Juan Miret; Paul Kirschmeier; Shohei Koyama; Yvonne Li; Glenn Dranoff, MD; Peter Hammerman; Chad Pecot; Kwok-Kin Wong, MD, PhD; Esra Akbay, PhD; | Granulocyte; Immune contexture; Immune suppression; Myeloid cells; Metabolism; Solid tumors; Tumor microenvironment |
| O36 | Neuropilin-1 stabilizes human Tregs in cancer patients leading to more potent suppressive function | Christopher A. Chuckran, BS; Anthony R. Cillo, PhD; Jessica Moskovitz, MD; Ashwin Somasundaram, MD; John M. Kirkwood, MD; Francesmary Modugno, PhD; Robert P. Edwards, MD; Robert Schoen, MD; Robert L. Ferris, MD, PhD; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; | Checkpoint blockade; Coinhibition; Costimulation; Cytokine; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
